A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

NCT06147037 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor
Metastatic Colorectal Carcinoma
Head and Neck Squamous Cell Carcinoma
Non-small Cell Lung Cancer
Pancreatic Ductal Adenocarcinoma
Gastric Cancer
Renal Cell Carcinoma

Interventions

DRUG: FPI-2053
DRUG: [111In]-FPI-2107
DRUG: [225Ac]-FPI-2068

Sponsor

AstraZeneca